同花顺（300033）iFinD数据显示，截至10月23日记者发稿时，按申万一级行业划分，逾50家医药生物 行业上市公司披露三季报。从归母净利润同比增速排名看，特一药业（002728）、富士莱（301258）、 沃华医药（002107）暂居前三，前三季度归母净利润同比增长速度分别为985.18%、430.16%、 179.34%；同时还有多家医药生物企业披露前三季度业绩预告。 值得关注的是，近期，不少医药生物上市公司在机构调研中透露行业发展新动向、海外市场开拓情况及 未来业绩展望等。 业内人士分析称，从医药行业三季度业绩前瞻看，CRO（合同研究组织）、CDMO（合同研发与生产 组织）等上游细分领域有望延续上半年业绩向好趋势，继续表现亮眼；中药、医疗器械、原料药、药店 等板块部分个股也有较为不错的业绩表现。同时，伴随近期2025年欧洲肿瘤内科学会（ESMO）大会的 数据披露以及BD（商务拓展）交易的持续落地，相关创新主线值得继续看好。 ● 本报记者 李梦扬 中药业务表现抢眼 根据同花顺iFinD数据，截至10月23日记者发稿时，在目前披露三季报的医药生物上市公司中，特一药 业前三季度归母净利润同比增速最高，达9 ...

● 本报记者 李梦扬 业内人士分析称，从医药行业三季度业绩前瞻看，CRO（合同研究组织）、CDMO（合同研发与生产 组织）等上游细分领域有望延续上半年业绩向好趋势，继续表现亮眼；中药、医疗器械、原料药、药店 等板块部分个股也有较为不错的业绩表现。同时，伴随近期2025年欧洲肿瘤内科学会（ESMO）大会的 数据披露以及BD（商务拓展）交易的持续落地，相关创新主线值得继续看好。 同花顺iFinD数据显示，截至10月23日记者发稿时，按申万一级行业划分，逾50家医药生物行业上市公 司披露三季报。从归母净利润同比增速排名看，特一药业、富士莱、沃华医药暂居前三，前三季度归母 净利润同比增长速度分别为985.18%、430.16%、179.34%；同时还有多家医药生物企业披露前三季度业 绩预告。 值得关注的是，近期，不少医药生物上市公司在机构调研中透露行业发展新动向、海外市场开拓情况及 未来业绩展望等。 迈瑞医疗在近日披露的投资者关系活动记录表中表示，公司预计2025年第三季度整体营业收入将实现同 比正增长，同时延续收入金额逐季度环比改善的趋势。 "分区域来看，国际市场方面，业务进度基本符合公司预期，预计从第三季度开始增 ...

Core Viewpoint - The first batch of semi-annual reports from Shenzhen-listed companies shows significant growth, particularly for WoHua Pharmaceutical, which has boosted investor confidence and provided a positive signal for the pharmaceutical industry [1][2]. Company Performance - WoHua Pharmaceutical reported a revenue of 425 million yuan, a year-on-year increase of 7.64%, and a net profit of 44.68 million yuan, up 303.16% year-on-year [2][3]. - In Q2 2025, WoHua achieved a revenue of 208 million yuan, a 15.39% increase, and a net profit of 21.82 million yuan, soaring by 1442.6% [2]. - WoHua plans to distribute a cash dividend of 1.20 yuan per share to all shareholders [2]. Factors Driving Growth - The substantial increase in net profit for WoHua is attributed to strong performance in its core business and effective cost control [3]. - The company's unique medical insurance products have gained clinical recognition, with six new authoritative guidelines added in H1 2025, enhancing their market penetration [3]. - The growth reflects a synergy between pricing power and cost management, with unique products mitigating the impact of centralized procurement [3]. Industry Trends - The county-level medical market is expected to be a key growth area for pharmaceutical companies over the next three years, with early movers likely to benefit from structural advantages [4]. - Recent government policies aimed at supporting the pharmaceutical industry, including increased funding for new drug development and promoting the consistency of generic drug quality, create a favorable external environment [4]. Other Company Performances - Other companies in the first batch, such as Changchuan Technology, JuCan Optoelectronics, and Ruihu Mould, also reported revenue and profit growth, with Changchuan achieving a revenue of 2.167 billion yuan, up 41.80%, and a net profit of 427 million yuan, up 98.73% [6][7]. - Ruihu Mould reported a revenue of 1.662 billion yuan, a 48.30% increase, and a net profit of 227 million yuan, up 40.33% [7]. - JuCan Optoelectronics achieved a revenue of 1.594 billion yuan, a 19.51% increase, and a net profit of 117 million yuan, up 3.43% [8]. Market Overview - As of July 15, 2025, 775 Shenzhen companies had disclosed their semi-annual performance, with 453 companies (approximately 58.45%) expecting a year-on-year increase in net profit [9]. - Among the top 100 Shenzhen companies by market capitalization, only one did not report profit growth, highlighting the resilience of leading firms in a complex global economic environment [9].

7月21日晚间，沃华医药（002107.SZ）披露的2025年半年报显示，今年上半年，沃华医药实现营业收入4.25亿元，同比增长7.64%；净利润4467.64万元， 同比增长303.16%。同时拟向全体股东每10股派发现金红利1.2元（含税）。 在医疗改革、原材料成本上涨的背景下，中成药龙头企业沃华医药（002107.SZ）上半年实现了盈利同比增长超3倍的亮眼业绩。 心脑血管系统药品营收同比增长快 亮眼的业绩背后，沃华医药主要的业绩驱动因素是什么？ "一降三增" 精简流程，赋能提效 盈利能力的大幅提升与沃华医药在管理、营销、研发等方面的布局不无关系。 沃华医药还提到，报告期内，公司持续聚焦主业，持续落实"实、细、严、简"的精细化管理要求，进一步强化"一降三增"（即降成本费用、增销售、增效 率、增现金）战略方针落地。生产方面，公司持续提升装备智能化水平，持续推动精益生产，提高各工序生产效率，千方百计降本增效。 半年报数据显示，在沃华医药主要产品线中，其心脑血管系统药品营业收入29423.04 万元，同比增长11.53%，增长幅度远超其他主要产品。 不容忽视的是，在长期需求旺盛的医药行业中，心脑血管、骨科等慢性 ...

Core Insights - Wuhua Pharmaceutical reported a more than threefold increase in net profit for the first half of 2025, achieving a net profit of 44.68 million yuan, a year-on-year growth of 303.16% [1] - The company’s revenue reached 425 million yuan, reflecting a year-on-year increase of 7.64% [1] - Wuhua plans to distribute a cash dividend of 1.2 yuan per 10 shares to all shareholders [1] Company Performance - The company has focused on refined management and academic promotion, implementing a strategy to reduce costs and increase sales, efficiency, and cash flow [1] - Wuhua holds 46 national invention patents and has 162 drug approval numbers, with 15 exclusive products covering various medical fields [2] - The company’s four major exclusive medical insurance products have been recommended in 93 authoritative textbooks, clinical guidelines, and expert consensus documents [2] Industry Context - The national healthcare reform and the strong foundation project provide opportunities for Wuhua to expand its market presence in grassroots healthcare [1][2] - Since February 2025, the construction of tightly-knit county medical communities has been promoted in 2,188 counties, with Wuhua's heart medication entering nearly 300 county medical community directories [2] - In the second quarter of 2025 alone, Wuhua's heart medication was added to 41 new directories [2]